BeOne Medicines Ltd. (ONC)
About BeOne Medicines Ltd.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $5.3B
- Net income
- $286.9M
- Total assets
- $8.2B
- Market cap
- $28.0B
- Gross margin
- 87.5%
- Operating margin
- 8.4%
- Net margin
- 5.4%
Source: SEC EDGAR · updated Jun 8, 2026
Financial statements
Income statement
- Revenue
- $5.3B
- Cost of revenue
- $668.5M
- Gross profit
- $4.7B
- Operating expenses
- $4.2B
- Operating income
- $447.1M
- Income tax
- $129.9M
- Net income
- $286.9M
- EPS (basic)
- $0.20
- EPS (diluted)
- $0.19
Balance sheet
- Total assets
- $8.2B
- Current assets
- $6.2B
- Total liabilities
- $3.8B
- Current liabilities
- $1.8B
- Shareholders’ equity
- $4.4B
Cash flow
- Operating cash flow
- $1.1B
- Investing cash flow
- -$276.2M
- Financing cash flow
- $1.1B
- Net cash flow
- $2.0B
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $28.0B
- P/E ratio
- 1715.3
- EPS (diluted)
- $0.19
- Shares outstanding
- 86.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 3, 2016
BeOne Medicines Ltd. (ONC) Stock Price
- Profitable — net income of $286.9M in FY2025.
- Gross margin of 87.5%, net margin 5.4%.
- Trading 14% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 1715.3.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BeOne Medicines Ltd..
Write a review
News about BeOne Medicines Ltd.
News & sentiment via Polygon.io
BeOne Medicines Ltd.: frequently asked questions
Is BeOne Medicines Ltd. an American company?
BeOne Medicines Ltd. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is BeOne Medicines Ltd. publicly traded?
Yes — BeOne Medicines Ltd. is a publicly traded company. Its stock trades under the ticker symbol ONC on the NASDAQ.
What does BeOne Medicines Ltd. do?
BeOne Medicines Ltd. is an American Pharmaceuticals company in the Health & Beauty sector.
